DR.Qaiser AS
Not financial advice. The index, rank, signals and advice are rule-based indications from the latest filed annual accounts. They are not a credit rating, an assessment of management or a recommendation to buy, sell or do business with the company. Read more
Key facts
Is the company run well?
Five key figures against companies in the Morning class Micro in the same sector. Green is better than most, amber about like the industry and red weaker than most.
- Profitability · operating margin 18.3% Better than the industry Industry: 8.9%
- Returns · return on assets 27.9% Better than the industry Industry: 18.9%
- Solidity · equity ratio 44.1% About like the industry Industry: 43.5%
- Liquidity · current ratio 1.79 About like the industry Industry: 1.56
- Growth · revenue growth 401.3% Better than the industry Industry: 4.1%
The mark comes from the company's place among comparable companies (percentile): green from 60, amber from 40, red below 40. Negative equity, an operating loss and a current ratio under 1 pull it down regardless. Methodology
Score · fiscal year 2025
55of 100
How to read this: the company is ahead of 58 % of companies in the Morning class Micro in the same sector in 2025. What does this mean?
Rank in the Morning class Micro: 2,339 of 5,525 · What are Morning company classes?
Place in the whole sector: 2,791 of 6,599 · Helse og omsorg
Profile
Cheetah · Sprinter
High profitability, lower resilience
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 64 and resilience 48 out of 100 among companies in the Morning class Micro in the same sector in 2025. Methodology
Against the sector
DR.Qaiser AS is 4 points above the median for companies in the Morning class Micro in the same sector in 2025.
Median score 51 among 5,517 companies.
Against companies in the Morning class Micro in the same sector in 2025: operating margin 18.3% (median 8.9%) and equity ratio 44.1% (median 43.5%).
How it has gone · 2024–2025
Revenue rose by 401 % from 2024 to 2025, to 2.2 MNOK. The operating margin fell from 92.6% in 2024 to 18.3% in 2025. The equity ratio fell from 71.8% in 2024 to 44.1% in 2025.
Amounts in the reporting currency. The full year-by-year table is further down under «Details». See every figure year by year
Accounts in short
| Key figure | 2024 | 2025 |
|---|---|---|
| Operating revenue | 0.4 MNOK | 2.2 MNOK |
| Operating profit | 0.4 MNOK | 0.4 MNOK |
| Net profit | 0.3 MNOK | 0.3 MNOK |
| Total assets | 0.5 MNOK | 1.5 MNOK |
| Equity | 0.4 MNOK | 0.7 MNOK |
| Total liabilities | 0.1 MNOK | 0.9 MNOK |
From the Brønnøysund Register Centre, in the company's reporting currency (NOK). See every figure year by year
From the Central Coordinating Register
- Org. no.
- 934384881
- Legal form
- AS
- Sector
- Helse og omsorg (86.210)
- Purpose
- Selge varer og tjenester innen allmennmedisin, og annet som naturlig sammenfaller med dette, samt deltakelse i andre selskaper, investeringer og nærliggende virksomhet.
- Morning company class
- Micro
- Employees
- 0–4 (not registered) Payroll costs in the accounts: 1.6 MNOK (2025).
- Founded
- 23 October 2024 2 years in operation
- Share capital
- 0.03 MNOK
- Business address
- Nordskogvegen 4, 9990 BÅTSFJORD
- Municipality
- Båtsfjord rank 18–28 of 28 in KOSTRA group 6
- Audit
- Audit opted out from 31 October 2024
- Latest accounts filed
- 2025
- VAT registered
- No
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
DR.Qaiser AS has a score of 55 for 2025, rank 2,791 of 6,599 in the sector.
Strongest: Profitability: percentile 64 against peers, operating margin 18.3% against a median of 8.9%.
No area is clearly below its peers.
Worth a closer look
- The change in operating margin in 2025 was 74.0 percentage points weaker than for comparable companies: the company −74.4, the industry −0.3 points. That is the company's own, not something that hit the whole industry.
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
Worth a closer look
No rules were triggered for this year.
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 1.0% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
See interest rates, prices and exchange rates for the sector
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2026, the sector's weakest year, for this company.
The sector's weakest year was 2026, with a median operating margin of −10.4%. Based on the 8 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 64 | weight 40% |
|---|---|---|
| Solidity | 47 | weight 20% |
| Liquidity | 56 | weight 5% |
| Growth | 49 | weight 25% |
| Consistency | 45 | weight 10% |
Three goals: profitability 40%, growth 25%, resilience 35%. Why these weights?
Index version 3. Data completeness 100%: the share of the weights that had data.
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 2 MNOK | 3 MNOK |
| Operating margin | 18.3% | 8.9% |
| Profit margin | 18.9% | 9.1% |
| Return on assets | 27.9% | 18.9% |
| Equity ratio | 44.1% | 43.5% |
| Debt-to-equity | 1.27 | 0.99 |
| Current ratio | 1.79 | 1.56 |
| Revenue growth | 401.3% | 4.1% |
The median and “ahead of” refer to companies in the Morning class Micro in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 55, DR.Qaiser AS does better than 58% of companies in the Morning class Micro in the same sector (5,525 companies) in 2025.
Score over time
Score over time needs at least two fiscal years with a score. It will appear when next year's figures are fetched or history is imported.
Working capital and debt
| Measure | Company | Median | |
|---|---|---|---|
| Working capital | |||
| Receivable days All current receivables, including those on group companies, in days of revenue. |
25 days | 14 days | |
| Inventory and other current assets, days Current assets other than receivables and bank deposits, that is inventory and short-term investments, in days of revenue. |
– | 0 days | |
| Net working capital to revenue Current assets less bank deposits less current liabilities, divided by revenue. Negative: short-term debt funds the operations. |
−31.7% | −9.6% | |
| Cash share of current assets How much of the short-term buffer is bank deposits and cash. |
90.0% | 75.9% | |
| Debt and interest burden | |||
| Interest coverage (times) Operating result divided by all financial costs. Below 1: operations do not cover the cost of the debt. |
48.2 | 38.0 | |
| Financial costs as a share of debt All financial costs (interest, currency losses and other) divided by all debt, interest-free debt included. Not an interest rate. |
1.0% | 0.3% | |
| Long-term share of debt Long-term debt as a share of all debt. A low share means more falls due within a year. |
– | 6.4% | |
Net working capital (current assets less bank deposits less current liabilities): −0.7 MNOK.
The median and the bar refer to companies in the Morning class Micro in the same sector in 2025. The bar shows the share of the group with a lower figure: higher is not always better, long receivable days tie up capital, for example. These figures do not count in the score.
The industry or the company: what drove the result?
In 2025 the operating margin of DR.Qaiser AS fell by 74.4 percentage points. Comparable companies fell by a median 0.3 points. So the company did 74.0 points weaker than the industry, for reasons of its own.
| Year | The company | Comparable (median) | Change, company | Change, industry | The company's own |
|---|---|---|---|---|---|
| 2025 | 18.3% | 8.9% | −74.4 percentage points | −0.3 percentage points | −74.0 percentage points |
Comparable companies are those in the same industry and Morning company class. Their change shows what hit the whole industry, the sector drivers below included. The rest is the company's own: contracts, costs, one-off items or operations. The share is approximate, and we claim no cause.
The company and its sector's drivers
Prices, rate and currency that shape the sector's year, year by year beside the operating margin of DR.Qaiser AS. The figures stand side by side; we claim no cause.
Consumer price index (indeks (2025 = 100))
Consumer price index rose 3.0% in 2025; the operating margin of DR.Qaiser AS fell 74.4 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Consumer price index, annual average | 84.3 | 89.2 | 94.1 | 97.0 | 100.0 | 103.0 (so far) |
| Change from the year before | +3.5% | +5.8% | +5.5% | +3.2% | +3.0% | +3.0% |
| The company's operating margin | – | – | – | 92.6% | 18.3% | – |
Source: SSB (14710, CC BY 4.0). Source
Policy rate (prosent)
Policy rate fell 0.20 percentage points in 2025; the operating margin of DR.Qaiser AS fell 74.4 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Policy rate, annual average | 0.08 | 1.32 | 3.54 | 4.50 | 4.30 | 4.17 (so far) |
| Change from the year before | −0.28 percentage points | +1.24 percentage points | +2.22 percentage points | +0.96 percentage points | −0.20 percentage points | −0.12 percentage points |
| The company's operating margin | – | – | – | 92.6% | 18.3% | – |
Source: Norges Bank (IR, NLOD 2.0). Source
Wage index: health services (indeks)
Wage index: health services rose 5.1% in 2025; the operating margin of DR.Qaiser AS fell 74.4 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Wage index: health services, annual average | 88.0 | 91.6 | 96.0 | 100.6 | 105.8 | 109.5 (so far) |
| Change from the year before | +2.5% | +4.1% | +4.7% | +4.9% | +5.1% | +3.6% |
| The company's operating margin | – | – | – | 92.6% | 18.3% | – |
Source: SSB (12314, CC BY 4.0). Source
We show the drivers and the margin side by side and claim no cause. Sensitivity per company is not computed until we have at least 10 years of accounts per company: with three years such figures are false precision.
What the numbers say
DR.Qaiser AS had an operating margin of 18.3% and an equity ratio of 44.1% in 2025, and ranks 2,791 of 6,599 in Helse og omsorg.
From 2024 to 2025: revenue grew by 401% and the operating margin fell from 92.6% to 18.3%.
This text is generated automatically from the 2025 accounts.
Three simple methods
The methods give between 0 MNOK and 7 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 18.8 | 4 MNOK |
| EV/EBIT | 23.4 | 7 MNOK |
| P/B | 1.1 | 0 MNOK |
| EV/EBIT: from enterprise value to equity | NOK |
|---|---|
| Enterprise value (EV) at the listed multiple | 10 MNOK |
| Enterprise value after the size adjustment | 6 MNOK |
| Less net debt (rough figure) | −1 MNOK |
| Equity value | 7 MNOK |
Net debt is a rough figure: long-term liabilities minus cash. The accounts do not split interest-bearing debt from other liabilities, and short-term borrowings are not included. The size adjustment applies to the enterprise value, not to the debt.
The listed basis is the value at listed multiples. The estimate is lowered for size: a small-company premium of 4% on the cost of equity gives a value 38% lower. No separate marketability discount is applied, because the premium already allows for the company being small and unlisted.
The multiples are from the listed industry that matches the NACE code (86): Hospitals/Healthcare Facilities.
Not financial advice. The value range is a rough model estimate from listed-company multiples, not a valuation, a price target or a price offer. The actual value may differ greatly. Read more
A mechanical estimate from public accounts, not advice. A mechanical estimate from public accounts with listed multiples and fixed adjustments. Not a valuation and not advice to buy or sell. See the calculation
Questions and answers
How profitable is DR.Qaiser AS?
The operating margin was 18.3% in 2025, against a median of 8.9% among companies in the Morning class Micro in the same sector. Return on assets was 27.9%.
How solid is DR.Qaiser AS?
The equity ratio was 44.1% in 2025 (median 43.5%). Debt-to-equity was 1.27 (median 0.99).
What is the liquidity of DR.Qaiser AS like?
The current ratio was 1.79 in 2025 (median 1.56).
How does DR.Qaiser AS compare in Helse og omsorg?
DR.Qaiser AS ranks 2,791 of 6,599 in Helse og omsorg for 2025. Among companies in the Morning class Micro it is number 2,339 of 5,525. Revenue changed by 401.3% from the year before.
Competitors
The 8 closest competitors in the same line of business, placed in the same matrix as the sector page: profitability up, resilience to the right. These are the companies the competitor analysis and the strategy report compare with.
Each bubble is a company: this company and its closest competitors in the same line of business and size, the same ones the competitor analysis uses. Placement is 0–100 against the whole sector and Morning company class: further right is more robust, higher up is more profitable. Bubble size is revenue. The light bubble and arrow show where the company stood the year before. Pick a profile to see fewer at a time.
| Company | Profile | Operating revenue | Operating margin | Score |
|---|---|---|---|---|
| Davis Medical AS |  Lion |
2 MNOK | 68.1% | 92 |
| Oslo Medical Center AS |  Beaver |
2 MNOK | 0.2% | 34 |
| DR. Moin Aldin AS |  Elephant |
2 MNOK | −0.6% | 28 |
| Mrc AS |  Cheetah |
2 MNOK | 7.0% | 38 |
| Kristiansund Sjømannslegekontor AS | Beaver |
2 MNOK | −17.6% | 18 |
| DR.Qaiser AS (this company) | Cheetah |
2 MNOK | 18.3% | 55 |
| Tatte AS | Beaver |
2 MNOK | −2.1% | 23 |
| Solsiden Legesenter AS | Beaver |
2 MNOK | 5.0% | 27 |
| Øystein Rønbeck AS | Beaver |
2 MNOK | −2.8% | 22 |
The selection is the closest in revenue within the same industry code. When you order, you can swap competitors. Order competitor analysis
Ownership and roles
Loading roles …
Source: Central Coordinating Register, fetched 5 November 2026. Only names are shown.
Shareholders (2025)
- Number of shareholders
- 1 (one owner)
- Largest owner
- 100.0%
- Split
- companies 0% · private persons 100% · foreign 0%
- Owned from the same municipality
- 100%
- Group chain
- Ultimate owner: private person
The company is new in the shareholder register in 2025.
Source: the Norwegian Tax Administration's shareholder register as of 2025. Figures may be older than today's ownership. Private persons are not shown by name.
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Is this your company? Suggest changes or add information
Figures last fetched 9 November 2026.
Year by year · 2024–2025
| Key figure | 2024 | 2025 | Trend |
|---|---|---|---|
| Index | – | 55 | |
| Rank | – | 2,791 | |
| Operating margin | 92.6% | 18.3% | |
| Return on assets | 84.2% | 27.9% | |
| Equity ratio | 71.8% | 44.1% | |
| Current ratio | 3.54 | 1.79 | |
| Revenue growth | – | 401.3% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2024 | 2025 |
|---|---|---|
| Operating revenue | 0.4 MNOK | 2.2 MNOK |
| Operating profit | 0.4 MNOK | 0.4 MNOK |
| Profit before tax | 0.4 MNOK | 0.4 MNOK |
| Tax expense | 0.1 MNOK | 0.1 MNOK |
| Net profit | 0.3 MNOK | 0.3 MNOK |
| Financial expenses | – | 0.0 MNOK |
| Total assets | 0.5 MNOK | 1.5 MNOK |
| Current assets | 0.5 MNOK | 1.5 MNOK |
| Equity | 0.4 MNOK | 0.7 MNOK |
| Retained earnings | 0.3 MNOK | 0.7 MNOK |
| Total liabilities | 0.1 MNOK | 0.9 MNOK |
| Current liabilities | 0.1 MNOK | 0.9 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 9 November 2026, accounts id 6381519.
Further
Similar companies
- Sport Medicine Science AS index 55, rank 2,788 · compare
- Frisk Helse AS index 55, rank 2,789 · compare
- Øyelege Akil AS index 55, rank 2,790 · compare
- Tannlegespesialistene AS index 55, rank 2,792 · compare
- Tannlege Trym Paulsen AS index 55, rank 2,794 · compare